Abstract
To the investigator and clinician, prostate-specific antigen (PSA) level is a seemingly perfect outcome measure because it is easily assessable, quantitative, reproducible, and inexpensive. Whether post-therapy decline in PSA reflects true clinical benefit, and whether post-therapy declines can be used as an intermediate endpoint for accelerated drug approval is still open to question. At present, no drug has been approved strictly on the basis of a post-treatment decline in PSA, as it is unproven that such PSA changes are surrogates for true clinical benefits. Post-therapy PSA changes have been associated with improved survival in patients with castrate metastatic disease. The role of PSA changes as potential surrogates of clinical benefit have only been explored to a limited degree because to date, only two prospective randomized trials showing a survival benefit have been reported. Such trials are necessary, but not a sufficient pre-requisite to explore the potential role of any outcome measure as an intermediate endpoint. The clear demonstration that a post-therapy PSA change can account for all of the treatment effects seen is not yet available. A cytotoxic drug that does not produce any PSA decline is unlikely to be effective, but the converse is not always true because not all PSA rises represent a treatment failure. It is important to recognize that there are a range of clinical benefits to patients that can improve the quality and possibly the duration of survival, independent of PSA.
Key Points
-
Owing to the bone tropism of prostate cancer, there are few effective standard methods of assessing whether or not a patient is responding to treatment
-
PSA is a seemingly ideal outcome measure because it is quantitative, reproducible, and inexpensive
-
Post-therapy changes in PSA have been associated with improved survival in patients with progressive castrate metastatic disease receiving systemic treatments
-
Demonstration that PSA accounts for all of the treatment effects seen has not yet been convincingly established
-
Post-treatment PSA decline should not be considered as an outcome that proves clinical benefit, and is not a surrogate for survival
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Scher HI and Heller G (2000) Clinical states in prostate cancer: towards a dynamic model of disease progression. Urology 55: 323–327
Thompson IM et al. (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med 349: 215–224
Beatty PA (2004) Prostate cancer with low PSA levels. N Engl J Med 351: 1802–1803
Thompson IM et al. (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 350: 2239–2246
D'Amico AV et al. (2004) Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351: 125–135
Kattan MW et al. (1998) A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90: 766–771
Kattan MW et al. (2000) Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol 18: 3352–3359
Partin AW et al. (1993) The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150: 110–114
D'Amico AV et al. (2004) Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure. J Natl Cancer Inst 96: 509–515
D'Amico AV et al. (2003) Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 95: 1376–1383
D'Amico AV et al. (2003) Cancer specific mortality following surgery or radiation for patients with clinically localized prostate cancer managed during the PSA era. J Natl Cancer Inst 95: 1376–1383
Scher HI et al. (2004) Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising PSA: recommendations from the prostate-specific antigen working group. J Clin Oncol 22: 537–556
Smith MR et al. (2005) Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 23: 2918–2925
Scher HI et al. (1996) Clinical trials in relapsed prostate cancer: defining the target. J Natl Cancer Inst 88: 1623–1634
Pound CR et al. (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281: 1591–1597
Tannock IF et al. (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502–1512
Petrylak DP et al. (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513–1520
Yagoda A et al. (1979) A critical analysis of response criteria in patients with prostatic cancer treated with cis-diamminedichloride platinum II. Cancer 44: 1553–1562
Yagoda A (1983) Cytotoxic agents in prostate cancer: an enigma. Semin Urol 1: 311–321
Scher HI et al. (1989) Cytotoxic chemotherapy in advanced carcinoma of the prostate: Memorial Sloan-Kettering Cancer Center experience. In Systemic Therapy for Genitourinary Tumors, 228–233 (Eds Johnson DE et al.) Chicago: Year Book Medical Publishers
Bubley GJ et al. (1999) Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the PSA Working Group. J Clin Oncol 17: 3461–3467
Therasse P et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205–216
Scher HI et al. (2005) Prostate cancer clinical trial end points: “RECIST”ing a step backwards. Clin Cancer Res 11: 5223–5232
Figg WD et al. (1996) Lack of correlation between prostate-specific antigen and the presence of measurable soft tissue metastases in hormone-refractory prostate cancer. Cancer Invest 14: 513–517
Fleming TR et al. (1997) Surrogate endpoints. AIDS Clin Rev 129–143
Guise TA and Mundy GR (1998) Cancer and bone. Endocr Rev 19: 18–54
Ferro MA et al. (1989) High-dose intravenous estrogen therapy in advanced prostatic carcinoma: use of prostate-specific antigen to monitor response. Urology 34: 134–138
Scher HI et al. (1990) Trimetrexate in prostatic cancer: preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease. J Clin Oncol 8: 1830–1838
Kelly WK et al. (1993) Prostate specific antigen as a measure of disease outcome in hormone-refractory prostatic cancer. J Clin Oncol 11: 607–615
Prentice RL (1989) Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 8: 431–440
Fleming TR and DeMets DL (1996) Surrogate end points in clinical trials: are we being misled. Ann Intern Med 125: 605–613
Scher HI et al. (1999) Post-therapy serum prostate specific antigen level and survival in patients with androgen-independent prostate cancer. J Natl Cancer Inst 91: 244–251
Smith DC et al. (1998) Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol 16: 1835–1843
Fossa SD et al. (2001) Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group. J Clin Oncol 19: 62–71
Thalmann GN et al. (1996) Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer. J Natl Cancer Inst 88: 794–801
Sridhara R et al. (1995) Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy. J Clin Oncol 13: 2944–2953
Verbel DA et al. (2002) Quantifying the amount of variation in survival explained by PSA. Clin Cancer Res 8: 2576–2579
Petrylak DP et al. (2004) SWOG 99-16: randomized phase III trial of docetaxel (D)/estramustine (E) versus mitoxantrone(M)/prednisone(p) in men with androgen-independent prostate cancer (AIPCA) [abstract #3]. J Clin Oncol 22
Roessner M et al. (2005) Prostate-specific antigen (PSA) response as a surrogate endpoint for overall survival (OS): analysis of the TAX 327 Study comparing docetaxel plus prednisone with mitoxantrone plus prednisone in advanced prostate cancer [abstract #4554]. Proc Am Clin Oncol 23: s391
Petrylak D et al. Evaluation of post treated on SWOG 99-16. JNCI, in press
Jain RK et al. (2006) Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 3: 24–40
Schatzkin A and Gail M (2002) The promise and peril of surrogate end points in cancer research. Nat Rev Cancer 2: 19–27
Strother JM et al. (2005) A phase II trial of weekly high-dose calcitriol and docetaxel in patients with locally advanced or metastatic pancreatic adenocarcinoma [abstract #94]. Proc Am Clin Oncol 23
Balk SP et al. (2003) Biology of prostate-specific antigen. J Clin Oncol 21: 383–391
Fortier AH et al. (1999) Antiangiogenic activity of prostate-specific antigen. J Natl Cancer Inst 91: 1635–1640
Miyata Y et al. (2003) Serum insulin-like growth factor binding protein-3/prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer. Prostate 54: 125–132
Denmeade SR et al. (2003) Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models. Prostate 54: 249–257
Shah RB et al. (2004) Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 64: 9209–9216
Beer TM et al. (2003) Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol 21: 123–128
Beer TM et al. (2004) Randomized study of high-dose pulse calcitriol or placebo prior to radical prostatectomy. Cancer Epidemiol Biomarkers Prev 13: 2225–2232
Small EJ et al. (2005) Immunotherapy (APC8015) for androgen independent prostate cancer (AIPC): final survival data from a phase 3 randomized placebo-controlled trial [abstract #264]. Proc Multidisciplinary Prostate Cancer Symposium
Saad F et al. (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94: 1458–1468
Johnson JR et al. (2003) End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 21: 1404–1411
Kelly WK et al. (2000) The development of biologic endpoints in patients treated with differentation agents: an experience with retinoids in prostate cancer. Clin Cancer Res 6: 838–846
Stephan C et al. (2006) Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update. Clin Chem 52: 59–64
Sartor O et al. (1998) Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer. Urology 52: 252–256
Small EJ et al. (2000) Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. J Clin Oncol 18: 1440–1450
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Fleming, M., Morris, M., Heller, G. et al. Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials. Nat Rev Clin Oncol 3, 658–667 (2006). https://doi.org/10.1038/ncponc0664
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncponc0664
This article is cited by
-
Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed
Nature Reviews Clinical Oncology (2023)
-
Integration of circulating tumor cell and neutrophil-lymphocyte ratio to identify high-risk metastatic castration-resistant prostate cancer patients
BMC Cancer (2021)
-
Stereotactic ablative radiotherapy in castration-resistant prostate cancer patients with oligoprogression during androgen receptor-targeted therapy
Clinical and Translational Oncology (2021)
-
Advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapy
Experimental Hematology & Oncology (2015)
-
Circulating tumor cells versus objective response assessment predicting survival in metastatic castration-resistant prostate cancer patients treated with docetaxel chemotherapy
Journal of Cancer Research and Clinical Oncology (2015)